MedPath

Canasa

These highlights do not include all the information needed to use CANASA safely and effectively. See full prescribing information for CANASA. CANASA (mesalamine) suppositor ies, for rectal use Initial U.S. Approval: 1987

Approved
Approval ID

89d91601-152b-4398-bebe-af1c023e9935

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 24, 2023

Manufacturers
FDA

Allergan, Inc.

DUNS: 144796497

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Mesalamine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code58914-501
Application NumberNDA021252
Product Classification
M
Marketing Category
C73594
G
Generic Name
Mesalamine
Product Specifications
Route of AdministrationRECTAL
Effective DateOctober 27, 2023
FDA Product Classification

INGREDIENTS (2)

fat, hardInactive
Code: 8334LX7S21
Classification: IACT
MESALAMINEActive
Quantity: 1000 mg in 1 1
Code: 4Q81I59GXC
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Canasa - FDA Drug Approval Details